Evidence of the massive opportunity for Bisantrene.
My analysis shows that Doxorubicin is used in 60% of chemotherapy regimens for HER- and HER+ Breast Cancers.
https://www.cancertherapyadvisor.co...ns/breast-cancer-invasive-treatment-regimens/
Immunomedics was bought out for USD $21B for a treatment that covers only about 15% of Breast Cancers.
See here for my full valuation. My current risk-adjusted valuation for Bisantrene and RACE is $66 for a buyout.
https://hotcopper.com.au/posts/51579160/single
Ann: Compelling Preclinical Breast Cancer Results, page-16
-
- There are more pages in this discussion • 238 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |